Patents by Inventor Lingyin Li
Lingyin Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240299532Abstract: Provided herein are vaccine delivery systems including a polymer hydrogel non-covalently crossed-linked with a plurality of nanoparticles, a dinucleotide adjuvant encapsulated in the hydrogel, and an antigen encapsulated in the hydrogel. The provided vaccine delivery systems are particularly useful for slowly releasing the antigen and adjuvant within a subject, thereby triggering a more therapeutically effective immune response. Also provided are kits including the disclosed vaccine delivery systems, and methods of using the disclosed materials.Type: ApplicationFiled: March 9, 2022Publication date: September 12, 2024Applicant: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Eric Andrew Appel, Emily C. Gale, Lingyin Li, Lauren J. Lahey
-
Publication number: 20230277570Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.Type: ApplicationFiled: May 16, 2023Publication date: September 7, 2023Inventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
-
Patent number: 11707471Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.Type: GrantFiled: September 30, 2022Date of Patent: July 25, 2023Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
-
Patent number: 11701371Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.Type: GrantFiled: September 7, 2018Date of Patent: July 18, 2023Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
-
Publication number: 20230190927Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a cell impermeable ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP 1. Also provided are vaccine compositions and methods relate thereto. Aspects of the methods include administering to a subject an effective amount of a cell impermeable ENPP1 inhibitor to inhibit the hydrolysis of cGAMP in combination with a vaccine.Type: ApplicationFiled: May 4, 2021Publication date: June 22, 2023Inventors: Lingyin Li, Randolph Mellus Johnson
-
Publication number: 20230103498Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.Type: ApplicationFiled: September 30, 2022Publication date: April 6, 2023Inventors: Lingyin Li, Mark Smith, Kelsey Erin Shaw, Jacqueline Ann Carozza, Volker Boehnert
-
Publication number: 20220289775Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with an ENPP1 inhibitor compound to inhibit the cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor compound is cell impermeable. ENPP1 inhibitor compounds can act extracellularly to block the degradation of cGAMP. Also provided are pharmaceutical compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of an ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject in conjunction with administering an ENPP1 inhibitor to the subject. The radiation therapy can be administered in the subject methods at a dosage and/or frequency effective to reduce radiation damage to the subject, but still instigate an immune response.Type: ApplicationFiled: January 30, 2020Publication date: September 15, 2022Inventors: Lingyin LI, Mark Smith, Jacqueline Ann CAROZZA, Volker BOEHNERT
-
Publication number: 20210369747Abstract: Compounds, compositions and methods are provided for the inhibition of ENPP1. Aspects of the subject methods include contacting a sample with a ENPP1 inhibitor to inhibit cGAMP hydrolysis activity of ENPP1. In some cases, the ENPP1 inhibitor is cell impermeable. Also provided are compositions and methods for treating cancer. Aspects of the methods include administering to a subject a therapeutically effective amount of a ENPP1 inhibitor to treat the subject for cancer. In certain cases, the cancer is a solid tumor cancer. Also provided are methods of administering radiation therapy to a subject either before or after administering an ENPP1 inhibitor. The radiation therapy can be administered at a dosage and/or frequency effective to reduce radiation damage to the subject. In certain cases, the method is performed in combination with a chemotherapeutic agent, or a checkpoint inhibitor, or both.Type: ApplicationFiled: September 7, 2018Publication date: December 2, 2021Inventors: Lingyin LI, Mark SMITH, Kelsey Erin SHAW, Jacqueline Ann CAROZZA, Volker BOEHNERT
-
Patent number: 9006394Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.Type: GrantFiled: January 23, 2014Date of Patent: April 14, 2015Assignee: Wisconsin Alumni Research FoundationInventors: Laura Lee Kiessling, Joseph R. Klim, Lingyin Li
-
Publication number: 20140287505Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.Type: ApplicationFiled: January 23, 2014Publication date: September 25, 2014Inventors: Laura Lee Kiessling, Joseph R. Klim, Lingyin Li
-
Patent number: 8648170Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.Type: GrantFiled: September 18, 2009Date of Patent: February 11, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Laura Lee Kiessling, Joseph Robert Klim, Lingyin Li
-
Publication number: 20100087004Abstract: The present invention relates to methods of growing and maintaining pluripotent cells on an insoluble substrate that presents a peptide that binds to glycosaminoglycans, such as heparin. Specifically, methods of growing and maintaining pluripotent cells on substrates having a chemically defined surface presenting at least one peptide having basic amino acid residues separated by one or two hydrophobic amino acid residues.Type: ApplicationFiled: September 18, 2009Publication date: April 8, 2010Inventors: Laura Lee Kiessling, Joseph Robert Klim, Lingyin Li